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Abstract
Background: Deletion or mutation(s) of the survival motor neuron 1 (SMN1) gene causes spinal
muscular atrophy (SMA). The SMN protein is known to play a role in RNA metabolism, neurite
outgrowth, and cell survival. Yet, it remains unclear how SMN deficiency causes selective motor
neuron death and muscle atrophy seen in SMA. Previously, we have shown that skin fibroblasts
from SMA patients are more sensitive to the DNA topoisomerase I inhibitor camptothecin,
supporting a role for SMN in cell survival. Here, we examine the potential mechanism of
camptothecin sensitivity in SMA fibroblasts.
Results: Camptothecin treatment reduced the DNA relaxation activity of DNA topoisomerase I
in human fibroblasts. In contrast, kinase activity of DNA topoisomerase I was not affected by
camptothecin, because levels of phosphorylated SR proteins were not decreased. Upon
camptothecin treatment, levels of p53 were markedly increased. To determine if p53 plays a role
in the increased sensitivity of SMA fibroblasts to camptothecin, we analyzed the sensitivity of SMA
fibroblasts to another DNA topoisomerase I inhibitor, -lapachone. This compound is known to
induce death via a p53-independent pathway in several cancer cell lines. We found that -lapachone
did not induce p53 activation in human fibroblasts. In addition, SMA and control fibroblasts showed
essentially identical sensitivity to this compound. By immunofluorescence staining, SMN and p53
co-localized in gems within the nucleus, and this co-localization was overall reduced in SMA
fibroblasts. However, depletion of p53 by siRNA did not lessen the camptothecin sensitivity in SMA
fibroblasts.
Conclusion: Even though p53 and SMN are associated, the increased sensitivity of SMA fibroblasts
to camptothecin does not occur through a p53-dependent mechanism.
Background
Spinal muscular atrophy (SMA) is a neuromuscular dis-
ease characterized by the loss of spinal motor neurons and
muscle atrophy [1]. SMA has an incidence of 1 in 6,000
live births, and is one of the most common genetic causes
of infant death [2,3]. Clinically, based on the age of onset
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and severity of the disease, childhood SMA can be catego-
rized into types I, II, and III [4,5]. Type I patients are diag-
nosed between the ages of zero to six months and cannot
sit unsupported or lift their heads, type II patients are
diagnosed between the ages of seven and 18 months and
can sit, and type III patients are older than 18 months
when diagnosed and can stand alone and walk but may
later lose these motor milestones. Although SMA shows a
broad spectrum of severity, genetic studies indicate that all
clinical phenotypes of SMA are caused by deletion or
mutation(s) of the survival motor neuron 1 (SMN1) gene
[6].
The SMN protein is ubiquitously expressed and localizes
in the cytoplasm as well as in the nucleus, where it is usu-
ally concentrated in subnuclear structures referred to as
"gems" (for Gemini of Cajal bodies [7,8]). The SMN pro-
tein plays an essential role in the biogenesis of small
nuclear ribonucleoprotein (snRNP) and small nucleolar
ribonucleoprotein (snoRNP) complexes [9-11]. SMN
appears to perform this function by associating with
Gemins 2–8 [12-14]. Recent studies have demonstrated
that the associated SMN/Gemin complex directly interacts
with specific domains of Sm proteins and uridine-rich
snRNAs to ensure stringent control of snRNP assembly
[15,16]. In addition to RNP assembly, SMN has been
shown to play a role in neurite outgrowth [17,18],
through its association with hnRNP R [19,20].
Complete loss of SMN in species ranging from S. pombe to
mice is lethal, indicating that SMN is critical for survival
of multiple cell types [21-23]. More direct evidence to sup-
port SMN's role in cell survival comes from studies in cul-
tured cells [24-29]. For example, depletion of the SMN
protein in Drosophila S2 cells stimulates caspase activity
and leads to increased cell death [25]. Importantly, SMN
has been shown to play a role in neuronal cell survival.
Depletion of SMN in differentiated P19 cells activates cas-
pase activity and increases cell death [27], whereas overex-
pression of human SMN (hSMN) protects differentiated
PC12 cells from cell death induced by neurotrophic factor
withdrawal [26].
Previously, we investigated the role of SMN in cell survival
using skin fibroblasts derived from SMA patients and age-
matched controls [29]. We demonstrated that SMA
fibroblasts display an increased sensitivity to camp-
tothecin-induced cell death. Treatment with menadione,
an agent causing cell death by generating oxidative stress
[30], did not cause differences in survival between SMA
and control fibroblasts. In addition, camptothecin treat-
ment resulted in significantly higher caspase-3 activity in
SMA fibroblasts when compared with control fibroblasts,
and this activity directly correlated with levels of SMN in
fibroblasts. Thus, these data support an active role for
SMN in cell survival.
Camptothecin is a specific DNA topoisomerase I inhibitor
that binds DNA topoisomerase I when the enzyme is com-
plexed with DNA [31]. Consequently, camptothecin sta-
bilizes the enzyme-DNA complex and suppresses the
enzymatic activity of this protein. Camptothecin has been
shown to induce cell death in human ovarian adenocarci-
noma cells via p53-dependent and independent pathways
[32]. Interestingly, SMN has been shown to interact with
p53, and this interaction is reduced when SMN harbors
mutations derived from SMA patients [33]. Because SMN
can interact with p53 and camptothecin can induce cell
death via p53-dependent and independent mechanisms,
this study addresses whether the increased sensitivity of
SMA fibroblasts to camptothecin occurs through a p53-
dependent mechanism. We found that although SMN
directly interacts with p53, the increased sensitivity of
SMN-depleted fibroblasts to camptothecin occurs
through a p53-independent mechanism.
Results
Camptothecin inhibits DNA unwinding but not kinase 
activity of DNA topoisomerase I in human fibroblasts
We previously showed that fibroblasts derived from SMA
patients have increased sensitivity to the DNA topoi-
somerase I inhibitor camptothecin [29]. DNA topoi-
somerase I has been shown to phosphorylate SR proteins
[34] that regulate RNA splicing. Considering SMN's role
in RNA splicing, we examined whether camptothecin
treatment would block phosphorylation of SR proteins in
SMA fibroblasts. Control and SMA fibroblasts were
treated with 25 M camptothecin, and levels of phospho-
rylated SR proteins in nuclear extracts were analyzed by
Western blotting using the mAb 104 antibody that specif-
ically recognizes a phosphorylated epitope at the
arginine/serine rich (RS) domain [35]. As shown in Figure
1A, levels of phosphorylated SR proteins were not reduced
in camptothecin-treated human fibroblasts. In fact, phos-
phorylation of some SR proteins was slightly increased,
which could be caused by activation of kinases other than
DNA topoisomerase I. These data suggest that camp-
tothecin does not inhibit in vivo kinase activity of DNA
topoisomerase I. Thus, the camptothecin-induced cell
death in human fibroblasts must be mediated by suppres-
sion of other enzymatic activities of DNA topoisomerase
I.
Next, we analyzed the DNA relaxation activity of DNA
topoisomerase I from human fibroblasts after camp-
tothecin treatment. Control and SMA fibroblasts were
treated with 25 M camptothecin, and DNA topoisomer-
ase I was immunoprecipitated. DNA relaxation activity of
this enzyme was assayed on a supercoiled plasmid DNABMC Cell Biology 2009, 10:40 http://www.biomedcentral.com/1471-2121/10/40
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Camptothecin inhibits DNA relaxation but not kinase activity of DNA topoisomerase I Figure 1
Camptothecin inhibits DNA relaxation but not kinase activity of DNA topoisomerase I. (A) Control and SMA 
fibroblasts were treated with 25 M camptothecin, and levels of phosphorylated SR proteins in the nuclear extracts were ana-
lyzed by Western blotting. The same blot was then stripped and reprobed with anti-histone 3 (H3) antibodies as a loading con-
trol. (B) DNA topoisomerase I was immunoprecipitated from camptothecin treated fibroblasts and subjected to the DNA 
unwinding assay. Plasmid DNA in the supercoiled form (SC) and in the relaxed form (R) is indicated. (C) DNA topoisomerase I 
immunoprecipitated from untreated control fibroblasts was subjected to the DNA unwinding assay in the presence of camp-
tothecin at the indicated concentrations. All the data shown here are representative of at least two independent experiments. 
CPT = camptothecin, H3 = histone 3, and Topo I = DNA topoisomerase I.
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[36]. Figure 1B shows that in the absence of DNA topoi-
somerase I, approximately half of the plasmid DNA was
found in the supercoiled form. Upon addition of this
enzyme, the majority of plasmid DNA was in the relaxed
form, and this DNA relaxation activity was inhibited by
camptothecin treatment. When immunoprecipitated
DNA topoisomerase I was mixed with camptothecin in
vitro, DNA relaxation activity of this enzyme was also
reduced (Fig. 1C), which is consistent with data obtained
from studies with purified DNA topoisomerase I [36,37].
Western blotting analyses indicated that upon camp-
tothecin treatment, levels of DNA topoisomerases I (~100
kD) in the immunoprecipitates and protein lysates were
reduced by 80% or more, and SMA fibroblasts had more
reduced levels of this enzyme than control fibroblasts
(90% [SMA] vs. 80% [control] at 4 h and 100% [SMA] vs.
88% at 8 h) (Figs. 2A and 2B). The reduction in DNA
topoisomerase I protein seems specific to camptothecin
since another DNA topoisomerase I inhibitor, -lapa-
chone, did not drastically affect levels of this enzyme (Fig.
2B). -lapachone directly binds to DNA topoisomerase I
and inhibits its enzymatic activity [38]. Thus, in vivo inhi-
bition of DNA topoisomerase I by camptothecin likely
results from a combination of decreased DNA relaxation
activity and reduced levels of this protein.
Activation of p53 and the sensitivity of SMA fibroblasts to 
the DNA topoisomerase I inhibitor -lapachone
Camptothecin has been shown to inhibit DNA topoi-
somerase I activity by stabilizing the enzyme-DNA cleav-
age complex [31]. As a result, camptothecin treatment
results in single- and double-stranded DNA breaks, causes
G1 and G2 arrests, and leads to cell death via p53-depend-
ent and independent pathways [32,39]. To elucidate
whether the increased sensitivity of SMA fibroblasts to
camptothecin is p53-dependent, we assessed p53 induc-
tion after camptothecin treatment. As shown in Figure 3A,
levels of p53 were markedly increased upon camptothecin
treatment, and this induction was seen as early as 4 h and
was sustained for 24 h. Treatment with menadione, which
also induces death in fibroblasts but does not show differ-
ential sensitivity between control and SMA fibroblasts
[29], did not elevate p53 levels (Fig. 3B). Unlike camp-
tothecin, menadione causes cell death by generating oxi-
dative stress [30]. This suggested that p53 could play a role
in the increased sensitivity of SMA fibroblasts to camp-
tothecin. To further address the role of p53 in camp-
tothecin sensitivity, we examined the sensitivity of SMA
fibroblasts to another DNA topoisomerase I inhibitor -
lapachone. This compound has been shown to induce cell
death via a p53-independent pathway in several cancer
cell lines [40]. Figure 3C shows that levels of p53 protein
were not elevated after -lapachone treatment; and p53
levels actually decreased by more than 70% under this
condition. Note that under the same treatment condi-
tions, levels of p53 were elevated two- to four-fold after
camptothecin treatment. The SMA fibroblasts showed no
increased sensitivity to -lapachone when compared with
control fibroblasts using the percentage of cell death as
the readout (Fig. 3D). These data imply that p53 plays a
role in the increased sensitivity of SMA fibroblasts to
camptothecin.
Camptothecin induces degradation of DNA topoisomerase I in fibroblasts Figure 2
Camptothecin induces degradation of DNA topoisomerase I in fibroblasts. (A) Presence of DNA toposiomerase I in 
the immunocomplexes described in 1B was confirmed by Western blotting analyses. (B) Fibroblasts described in 1B were 
treated with 25 M camptothecin or 25 M -lapachone, and DNA topoisomerase I present in the lysates was detected by 
Western blotting. The same blots were stripped and reprobed with anti--tubulin antibodies as a loading control. Relative 
ratios of DNA topoisomerase I to tubulin levels are indicated. All the data shown here are representative of at least two inde-
pendent experiments. CPT = camptothecin, Topo I = DNA topoisomerase I, IP = immunoprecipitation, IB = immunoblotting, 
and -LP = -lapachone.
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Figure 3 (see legend on next page)
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Association of p53 and SMN in SMA fibroblasts
Since an interaction of p53 with SMN has been previously
reported [33], we investigated whether p53 is associated
with SMN in fibroblasts. Immunoprecipitation analyses
of the endogenous p53 and SMN proteins did not show
an association (data not shown), indicating that SMN and
p53 interaction in fibroblasts is likely transient and not
stable. We next determined if a fraction of endogenous
p53 and SMN was associated by using confocal micros-
copy to test for co-localization. Co-localization of these
two proteins was confirmed by visualizing orthogonal
projections of stacked images. Control and SMA fibrob-
lasts were left untreated or treated with camptothecin, and
p53 and SMN proteins were detected by double-labeled
immunofluorescence staining. As shown in Figure 4A,
both p53 and SMN were localized in the cytoplasm and
the nucleus. Upon camptothecin treatment, p53 staining
in the nucleus was dramatically enhanced, which is con-
sistent with the p53 induction measured by Western blot-
ting analyses (see Figs. 3A and 3C). Nuclear
immunofluorescence staining showed that SMN was
more concentrated in gems, and that SMA fibroblasts had
reduced numbers of gems in the nucleus both in the
absence and presence of camptothecin treatment (Fig. 4A
and Table 1). Gem size in SMA fibroblasts was also
smaller than that in control fibroblasts (Table 1), likely as
a result of reduced levels of SMN expression in these cells.
In addition, SMN and p53 were seen to co-localize in
gems in the absence and presence of camptothecin (Figs.
4A and 4B). Overall, co-localization of SMN with p53 was
reduced in SMA fibroblasts (Table 1). For example, in the
absence of camptothecin treatment, control fibroblasts
had 99% gems with SMN/p53 co-localization, whereas
SMA fibroblasts had 75%–83%. Upon camptothecin
treatment, both number of gems and percentage of gems
with co-localized SMN/p53 were reduced in control, type
II, and type III SMA fibroblasts. Interestingly, type I SMA
fibroblasts had the fewest number of gems, but SMN and
p53 co-localized in almost all gems (only one of all
counted gems did not contain co-localized SMN and
p53).
Increased sensitivity of SMA fibroblasts to camptothecin is 
p53-independent
Having confirmed the association between SMN and p53
in fibroblasts, we determined if the susceptibility of SMA
fibroblasts to camptothecin is mediated by p53. Endog-
enous p53 protein in fibroblasts was depleted by siRNA,
and the sensitivity of SMA fibroblasts to camptothecin
was analyzed. Figures 5A and 5B showed a time course for
p53 depletion by siRNA in fibroblasts. A reduction of
approximately 85–90% in p53 mRNA levels was observed
by addition of p53 siRNA nucleotides at each time point
analyzed (Fig. 5A). Similarly, levels of the p53 protein
were reduced by more than 90% in p53 siRNA transfected
cells (Fig. 5B). Levels of p53 in non-targeting control and
mock transfected cells were indistinguishable, indicating
that p53 depletion by siRNA is specific. Moreover, upon
camptothecin treatment, levels of p53 were markedly ele-
vated in fibroblasts, and the increase in p53 expression
upon camptothecin treatment was completely eliminated
by p53 siRNA (Fig. 5C). Cell survival analyses indicated
that SMA fibroblasts were more sensitive to camptothecin
than control fibroblasts (~70% survival in control vs.
~35% in SMA fibroblasts after 25 M camptothecin treat-
ment) (Fig. 6A). Surprisingly, depletion of p53 by siRNA
did not rescue either control or SMA fibroblasts from
camptothecin-induced cell death. Figure 6A showed that
cell death induced by camptothecin was not significantly
reduced by p53 depletion. Our previous study showed
that SMA fibroblasts have significantly higher caspase-3
activity upon camptothecin treatment than control
fibroblasts [29], thus we analyzed induction of camp-
tothecin activated caspase-3 activity in p53 depleted
fibroblasts after camptothecin treatment. Figure 6B
showed that p53 depletion indeed decreased camp-
tothecin-induced PARP cleavage, an in vivo caspase-3 sub-
strate, in both control and SMA fibroblasts. This is
Activation of p53 and cell death induced by the DNA topoisomerase I inhibitors camptothecin and -lapachone Figure 3 (see previous page)
Activation of p53 and cell death induced by the DNA topoisomerase I inhibitors camptothecin and -lapa-
chone. (A) A type I SMA fibroblasts as described [29] were treated with 25 M camptothecin and levels of p53 were analyzed 
by Western blotting. The same blots were stripped and reprobed with anti--tubulin antibodies as a loading control. (B) A type 
II/III SMA fibroblasts as described [29] were treated with 10 M menadione and levels of p53 were analyzed as described for 
(A). (C) Control and SMA fibroblasts were treated with 25 M camptothecin or 25 M -lapachone and levels of p53 were 
analyzed as described for (A). Relative ratios of p53 to tubulin levels are indicated. (D) Three control and three SMA fibroblasts 
(one type I, one type II, and one type III) were treated with camptothecin for 72 h or -lapachone for 24 h at the indicated con-
centrations, respectively. Cell survival of treated cells was measured by the CellTiter-Blue assay, and the relative cell viability 
was calculated and presented as percentage of the untreated cells. Each condition was set up as replicates of four and repeated 
three times. The data presented here are combined mean values ± sem for three control and three SMA fibroblasts. Statistical 
analyses (unpaired t test) indicate that SMA fibroblasts are significantly sensitive to camptothecin at each tested concentration 
than control fibroblasts (*** p < 0.0001 and ** p < 0.001). CPT = camptothecin, -LP = -lapachone, MENA = menadione, and 
ND = non-detected.BMC Cell Biology 2009, 10:40 http://www.biomedcentral.com/1471-2121/10/40
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Association of SMN and p53 in fibroblasts Figure 4
Association of SMN and p53 in fibroblasts. (A) Control and SMA fibroblasts were left untreated or treated with 25 M 
camptothecin for 8 h. Camptothecin-treated cells were fixed and stained with anti-p53 (mouse) and anti-SMN (rabbit) antibod-
ies. Secondary antibodies were either labeled with Alexa 555 (anti-mouse, in red) or FITC (anti-rabbit, in green). Images of p53 
and SMN were taken by confocal microscope (63×). Phase contrast images (DIC) for the immunostained cells are included. 
Scale bar is 10 m. Gems are indicated by arrows. (B) Representative orthogonal views from z-stacking images of untreated 
control fibroblasts in (A) are shown here. The arrows indicate co-localization between SMN and p53. SMN = survival motor 
neuron, CPT = camptothecin, and DIC = differential interference contrast.
A
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consistent with caspase-3 being downstream of p53 [41].
Given that p53 depletion reduced caspase-3 activity but
this was not enough to rescue fibroblasts from camp-
tothecin-induced cell death, non-caspase-3 pathways
could also be involved in camptothecin-induced death in
SMA fibroblasts. When these findings are taken together,
we conclude that camptothecin-induced cell death in
human fibroblasts is not p53-dependent, and p53 does
not play a direct role in the increased sensitivity of SMA
fibroblasts to camptothecin.
Discussion
The critical feature in the pathogenesis of SMA is that
reduced levels of the SMN protein result in selective loss
of motor neurons accompanied by muscle wasting. SMN
has been shown to play a role in the assembly of RNP
complexes [9-11], transcription regulation [42], neurite
outgrowth [17-19], and cell survival [24-29]. However,
how SMN deficiency causes death of motor neurons and
muscle paralysis with little effect on other cells and tissues
remains unclear. Previously, we demonstrated that SMA
fibroblasts are more sensitive to camptothecin-induced
cell death when compared with control fibroblasts [29],
supporting a role for SMN in cell survival. In this study, we
further explored the potential mechanism(s) underlying
the susceptibility of SMA fibroblasts to camptothecin.
Camptothecin is a specific inhibitor of DNA topoisomer-
ase I. The best-characterized enzymatic activity of DNA
topoisomerase I is the relaxation of supercoiled DNA dur-
ing DNA replication and RNA synthesis [31]. Camp-
tothecin suppresses the DNA relaxation activity of DNA
topoisomerase I by stabilizing the topoisomerase I-DNA
cleavage complex [31,43]. As a result, camptothecin treat-
ment introduces single- and double-stranded DNA
breaks, leading to chromosome fragmentation and, even-
tually, cell death [39,43]. The action of camptothecin on
the DNA relaxation activity of DNA topoisomerase I has
been extensively characterized in vitro. Here, we used
immunoprecipitated DNA topoisomerase I to analyze in
vivo  DNA relaxation activity in camptothecin-treated
human fibroblasts. We found that DNA topoisomerase I
from camptothecin-treated fibroblasts had decreased
DNA relaxation activity (Fig. 1B), which may be due to
reduced levels of this protein and/or reduced enzymatic
activity. A reduction in the levels of DNA topoisomerase I
in human fibroblasts after camptothecin treatment could
be mediated by proteasome-dependent degradation as
previously reported for some cancer cell lines [44]. Inter-
estingly, the reduced levels of DNA topoisomerase I after
camptothecin treatment were more pronounced in SMA
fibroblasts (Figs. 2A and 2B). In addition, in the absence
of camptothecin, overall levels of DNA topoisomerase I
were lower in SMA fibroblasts than control fibroblasts
(Figs. 2A and 2B). Thus, the lower levels of DNA topoi-
somerase I in SMA fibroblasts could account for their
increased susceptibility to camptothecin. Further experi-
ments are needed to determine if the increased sensitivity
of SMA fibroblasts to camptothecin is due to lower levels
of DNA topoisomerase I in these cells. In addition to its
DNA relaxation activity, DNA topoisomerase I exhibits a
kinase activity that phosphorylates SR proteins [34]. Since
camptothecin treatment of SMA fibroblasts did not result
in reduced levels of phosphorylated SR proteins, camp-
tothecin probably did not inhibit kinase activity of DNA
topoisomerase I in vivo. Thus, inhibition of the DNA relax-
ation activity of DNA topoisomerase I by camptothecin
likely accounts for its cytotoxicity in human fibroblasts.
In human ovarian adenocarcinoma cells, camptothecin
has been shown to induce cell death via p53-dependent
and independent pathways [32]. The present study
showed that levels of p53 were markedly increased in
SMA fibroblasts upon camptothecin treatment (Figs. 3A,
C, and 4A). Our data also confirmed previous findings
[33] in which a fraction of p53 co-localized with SMN in
gems, and this co-localization was overall decreased in
SMA fibroblasts (Table 1). However, depletion of p53 by
siRNA did not lessen the susceptibility of SMA fibroblasts
to camptothecin (Fig. 6). Thus, although p53 is activated
by camptothecin and p53 and SMN can associate in vivo,
p53 does not play a direct role in the increased sensitivity
of SMN-depleted fibroblasts to camptothecin. This agrees
with a previous study performed in SMA transgenic mice
Table 1: Co-localization of SMN with p53 in fibroblasts
Type I Type II Type III Control
Untreated
Gem number/100 cells 6 16 24 114
Average gem size ± SD (nm) 538 ± 37 603 ± 73 649 ± 121 715 ± 153
% of co-localization with p53 83.3 75.0 75.0 99.1
CPT treated
Gem number/100 cells 6 11 17 80
Average gem size ± SD (nm) 544 ± 22 542 ± 53 689 ± 154 793 ± 173
% of co-localization with p53 100.0 63.0 64.7 85.0BMC Cell Biology 2009, 10:40 http://www.biomedcentral.com/1471-2121/10/40
Page 9 of 14
(page number not for citation purposes)
Depletion of the p53 protein in fibroblasts by RNA interference Figure 5
Depletion of the p53 protein in fibroblasts by RNA interference. (A) Control fibroblasts transfected with p53, non-tar-
geting control, or no siRNA oligonucleotides (mock) were harvested at the indicated times. Levels of p53 mRNA was meas-
ured by real-time TaqMan PCR using p53 as the target and gusB as the endogenous control. Statistical analyses (one-way 
ANOVA) indicate a significant reduction of p53 mRNA by the addition of p53 siRNA at each time point analyzed as compared 
to mock control (*** p < 0.0001). The data shown here are representative of two independent experiments. (B) A similar 
experiment was conducted as described for (A), and levels of the p53 protein were detected as described for 2A. (C) Control 
and SMA fibroblasts were transfected as described for (A). Twenty-four hours after transfection, cells were treated with 25 
M camptothecin for 24 h. Levels of p53 were analyzed as described for (B). NT = non-targeting control, CPT = camptothecin, 
and ND = non-detected.
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Depletion of the p53 protein does not lessen the camptothecin susceptibility in SMA fibroblasts Figure 6
Depletion of the p53 protein does not lessen the camptothecin susceptibility in SMA fibroblasts. (A) A similar 
experiment was conducted as described for 5C. Cell survival of treated cells was measured and presented as percentage of the 
untreated ones. At least two independent experiments were performed and each sample was set up in replicates of four. The 
mean value ± sem of one representative experiment is presented here. Statistical analyses (unpaired t test) indicate that SMA 
fibroblasts are significantly more sensitive to camptothecin than control fibroblasts (*** p < 0.0001). There is no difference in 
survival among cells transfected with non-targeting control, p53, or no siRNA oligonucleotides for either control or SMA 
fibroblasts. (B) A similar experiment was conducted as described for 5C except cells were treated with 25 M camptothecin 
for 16 h. Cell lysates were analyzed by Western blotting using antibodies against cleaved PARP, p53, and tubulin, respectively. 
NT = non-targeting control, CPT = camptothecin, and cPARP = cleaved poly ADP-ribose polymerase.
A
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[45]. This study indicated that elimination of p53 does
not alleviate the disease severity or extend overall lifespan
in type I and type III SMA mice. Thus, p53-independent
apoptotic pathways may play a role in motor neuron loss
when SMN is depleted.
Analyses of the sensitivity of SMA fibroblasts to another
DNA topoisomerase I inhibitor, -lapachone, indicate
that SMA and control fibroblasts showed similar sensitiv-
ity to this compound (Fig. 3D). -lapachone is known to
induce cell death in several cancer cell lines through a
p53-independent pathway [40]. Our data showed that
this compound did not induce p53 in fibroblasts (Fig.
3C), suggesting that p53 is not involved in -lapachone-
induced cell death in fibroblasts. Unlike camptothecin, -
lapachone directly binds to DNA topoisomerase I and
inhibits its enzymatic activity [38]. Thus, -lapachone
treatment usually does not cause DNA damage [38]. We
noticed that -lapachone did not induce a drastic reduc-
tion in the levels of DNA topoisomerase I (Fig. 2B). Since
a reduction in DNA topoisomerase I protein by camp-
tothecin seems to be triggered by DNA damage [44], it is
possible that -lapachone did not cause DNA damage in
human fibroblasts, so levels of DNA topoisomerase I pro-
tein remained unaltered after -lapachone treatment.
Thus, the increased sensitivity of SMA fibroblasts to camp-
tothecin but not to -lapachone suggests that cell death
pathways activated by DNA damage may be responsible
for the susceptibility of SMA fibroblasts to camptothecin.
SMN may protect fibroblasts from camptothecin-induced
cell death through this pathway. This hypothesis is further
supported by our observation that in addition to camp-
tothecin, SMA fibroblasts show an increased sensitivity to
other DNA damaging reagents (C. Wu, unpublished
data). It will be interesting to find out whether other
apoptotic molecules in this pathway such as Bax play a
role in the vulnerability of SMA fibroblasts to camp-
tothecin, since abolishing this apoptotic protein clearly
protects SMA mice from motor neuron loss [46].
Conclusion
Our results confirm that p53 is activated by camptothecin
in human fibroblasts. In addition, p53 co-localizes with
SMN in gems, and this co-localization is overall reduced
in SMA fibroblasts. However, p53 does not directly affect
camptothecin sensitivity when SMN is depleted.
Methods
Cell culture and transfection
Skin biopsies from SMA patients and controls were
obtained as part of a study approved by the Institutional
Review Board of the Alfred I. duPont Hospital for Chil-
dren. Human fibroblast cell lines were established from
these biopsies and maintained according to standard pro-
tocols [29]. In brief, fibroblasts were maintained in
DMEM supplemented with 20% fetal bovine serum and
antibiotics. Passage numbers for control and SMA fibrob-
lasts were matched as closely as possible for all experi-
mental procedures and always kept  #25. These
fibroblasts were used in our previous studies [29,47].
Unless specifically denoted, SMA fibroblasts used in this
study are not the cell lines used in our initial published
study [29]. The number of SMN1 and SMN2 gene copies
for control and SMA fibroblasts were determined by quan-
titative real-time PCR as described [47]. Control fibrob-
lasts carry two copies of SMN1 and two copies of SMN2.
All SMA fibroblasts have zero copies of SMN1. For the
SMN2 gene, most type I fibroblasts contain two copies,
type II mainly carry three copies, and type III carry three or
more copies. For RNA interference (RNAi) analyses, 1 ×
106 fibroblasts were electroporated with 100 nM of small
interference RNA (siRNA) oligonucleotides in nucleofec-
tor solution optimized for primary fibroblasts following
manufacturer's instruction (Amaxa, Gaithersburg, MD).
siRNA oligonucleotides (SMARTpool kits) for human p53
(p53 SMART pool, L-003329) and non-targeting control
(siGenome non-targeting siRNA, D-001206-14) were pur-
chased from Dharmacon (Chicago, IL).
Analysis of p53 transcript levels by real-time PCR
For p53 RNAi validation, control fibroblasts were trans-
fected with no siRNA (mock), non-targeting control, or
p53 siRNA oligonucleotides. Cells were harvested at 24,
48, and 72 h after transfection. Total RNA was isolated
using the RNeasy kit with on-column DNase treatment
(Qiagen, Los Angeles, CA). First-strand cDNA synthesis
was carried out with the Omniscript kit (Qiagen). The
real-time PCR was performed in a total volume of 15 l,
containing 10 ng of cDNA, 1× TaqMan Universal PCR
master mix (Applied Biosystems, Atlanta, GA), and 1×
p53 gene expression assay (Hs01034253) from Applied
Biosystems. The real-time PCR was performed on a 7900
HT Sequence Detection System (Applied Biosystems)
using a 384-well format, and amplification was achieved
using the standard amplification protocol. To enable nor-
malization of the input target cDNA added to each well,
the endogenous control GusB (GusB gene expression
assay, 4333767F, Applied Biosystems) was amplified
simultaneously in a separate reaction well but under iden-
tical thermal cycling conditions. Each reaction was run in
triplicate and each sample was run at least twice. Amplifi-
cation data were analyzed using the Sequence Detection
Software SDS 2.2 (Applied Biosystems) and running rela-
tive quantification (RQ) studies where p53 was identified
as the target and GusB as the endogenous control.
Western blotting analyses and immunoprecipitation
For p53 RNAi validation at the protein levels, control
fibroblasts were transfected with no siRNA (mock), non-BMC Cell Biology 2009, 10:40 http://www.biomedcentral.com/1471-2121/10/40
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targeting control, or p53 siRNA oligonucleotides. Cells
were harvested at 24, 48, and 72 h after transfection.
Lysates from fibroblasts were prepared, protein concentra-
tion was measured by the BCA assay, and Western blotting
analyses were performed as previously described [29]. In
brief, 50 g of protein lysates was resolved on 7.5% SDS-
PAGE for DNA topoisomerase I detection, 10% SDS-
PAGE for phosphorylated SR proteins, histone 3 (H3),
and cleaved PARP detection, or 12% SDS-PAGE for p53,
SMN, and -tubulin detection. Blots were probed with
antibodies against DNA topoisomerase I (1:50, hybrid-
oma 8G6 supernatant, a kind gift from Dr. Daniel Sim-
mons at the University of Delaware, USA) [37]),
phosphorylated SR proteins (mAB 104, 1:1000, a kind gift
from Dr. Paula Grabowski at the University of Pittsburgh,
USA) [35]), histone 3 (1:1000, Cell Signaling, Danvers,
MA), cleaved PARP (1:200, Millipore, Billerica, MA), p53
(1:500, Santa Cruz Biotechnology, Santa Cruz, CA), SMN
(1:1000, BD Sciences, San Jose, CA), and -tubulin
(1:500, Santa Cruz). The blots were then incubated with
the appropriate secondary HRP-conjugated antibodies,
and proteins were detected using enhanced chemilumi-
nescence (AmershamPharmacia). Signals were quantified
using Image J (National Institute of Health, Bethesda,
MA). The ratios of p53 or DNA topoisomerase I to tubulin
levels were calculated.
For immunoprecipitation of human DNA topoisomerase
I, fibroblasts were left untreated or treated with 25 M
camptothecin for 4 or 8 h. Cell lysates were prepared, and
750 g of cell lysates in 1 ml of lysis buffer as described
above was incubated with 2.5 g of purified monoclonal
anti-DNA topoisomerase I antibody 8G6 plus protein A/
G beads (Santa Cruz) at 4°C overnight. The immunocom-
plex was extensively washed with lysis buffer and then
with DNA relaxation assay buffer and subjected to DNA
unwinding assay (see below), or eluted with SDS sample
buffer, which preceded Western blotting analyses. Similar
results were obtained for both time points, and only
results obtained at 4 h are shown in Figure 2A.
DNA unwinding assays
Fibroblasts were left untreated or treated with 25 M
camptothecin for 4 or 16 h. DNA topoisomerase I was
immunoprecipitated and assayed for DNA unwinding
activity as described [36]. In brief, immunoprecipitated
DNA topoisomerase I was incubated with 1 g of pBlue-
script plasmid DNA (Stratagene, La Jolla, CA) in 20 l of
relaxation buffer (10 mM Tris-HCl, pH 7.5, 50 mM KCl, 5
mM MgCl2, 0.1 mM EDTA, 0.5 g/ml BSA, and 0.2 mM
DTT) for 30 min at 37°C. The reaction was stopped by
adding 6 l of loading buffer containing 50 mM EDTA,
0.5% SDS, 0.1% bromophenol blue, and 50% (w/v)
sucrose. The samples were separated by electrophoresis in
1% agarose gels in TBE buffer (30 mM Tris base, 90 mM
boric acid, and 2 mM EDTA, pH 8.0). DNA bands were
visualized by ethidium bromide staining. Similar results
were obtained for both time points, and only results
obtained at 4 h are shown in Figure 1B. To assess in vitro
the inhibitory effect of camptothecin on enzymatic activ-
ity, the immunoprecipitated DNA topoisomerase I from
untreated fibroblasts was incubated with plasmid DNA in
the presence of camptothecin, and the DNA unwinding
activity was assayed as described above.
Nuclear extract preparations
Control and SMA fibroblasts seeded on 100-mm dishes at
a density of 1 × 106 per dish were left untreated or treated
with 25 M camptothecin. Treated cells were harvested at
0, 4, and 16 h after treatment, and resuspended in hypot-
onic lysis buffer (10 mM HEPES, pH 7.9 containing 1.5
mM MgCl2, 10 mM KCl, 0.2 mM PMSF, and 0.5 mM dithi-
othreitol). Cells were allowed to swell for 10 min and after
that homogenized. The nuclei were collected by centrifu-
gation, and resuspended in lysis buffer as described
above. After 20-min incubation on ice, lysates were centri-
fuged at 13,200 rpm for 15 min at 4°C, and the protein
concentration of nuclear extracts was measured by the
BCA assay. Fifty micrograms of nuclear extracts was sub-
jected to Western blotting analyses using antibodies
against the phosphorylated SR proteins and histone 3.
Chemical treatments and cell survival assays
For p53 activation analysis, approximately 1 × 106 fibrob-
lasts were seeded on 100-mm dishes. Eighteen hours after
seeding, cells were left untreated or treated with camp-
tothecin (Sigma, St. Louis, MO), -lapachone (Biomol,
Plymouth Meeting, PA), or menadione (Sigma) at the
indicated time points (Fig. 3). Activation of p53 was ana-
lyzed by Western blotting (see above). For analysis of cell
survival, fibroblasts were seeded on 96-well plates at a
density of 3 × 104 cells/well. Eighteen hours after seeding,
cells were washed three times with 0.5% BSA in DMEM
and exposed to either camptothecin for 72 h or -lapa-
chone for 24 h at the indicated concentrations (Fig. 3D).
Cell viability of treated cells was measured by the Cell-
Titer-Blue assay following manufacturer's recommenda-
tions (Promega, Madison, WI). All treatment conditions
were set up on three control and three SMA fibroblasts
and each condition was assayed in quadruplicate. The rel-
ative cell viability was calculated for each condition. The
results for three control and SMA fibroblasts were com-
bined and presented as the percentage of the untreated
cells. For cell survival analyses in p53-depleted fibroblasts,
approximately 6 × 104 transfected fibroblasts were seeded
on 96-well plates. Twenty-four hours later, cells were
treated with 5 or 25 M camptothecin for 24 or 48 h. Cell
survival was measured by the CellTiter-Blue assay
(Promega). Similar results were obtained for both time
points, and only results obtained at 24 h are shown in Fig-BMC Cell Biology 2009, 10:40 http://www.biomedcentral.com/1471-2121/10/40
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ure 6A. For the activation of caspase-3 in p53-depleted
fibroblasts, approximately 1 × 106 transfected cells were
seeded on 100-mm dishes. Twenty-four hours later, cells
were treated with 25 M camptothecin for 16 h, and the
activation of caspase-3 in vivo was analyzed by detection
of cleaved PARP by Western blotting as described above.
Immunofluorescence
Fibroblasts were washed in phosphate-buffered saline
(PBS) and fixed with 4% paraformaldehyde in PBS for 10
min at room temperature. After two washes with PBS, cells
were permeabilized with 0.2% Triton X100 for 15 min,
washed twice with PBS, and blocked with 5% bovine
serum albumin in Tris-buffered saline containing 0.05%
Tween-20 (TBST) for 1 h. Cells were then incubated over-
night at 4°C with polyclonal anti-SMN antibodies (1:100,
Santa Cruz), or monoclonal anti-p53 antibody (1:100,
Santa Cruz) diluted in blocking buffer. After three TBST
washes, the cells were then incubated with Alexa fluor-
555 conjugated anti-mouse antibodies (1:600, Invitrogen,
Chicago, IL) or FITC-conjugated anti-rabbit antibodies
(1:200; Jackson ImmunoResearch Laboratories, West
Grove, PA) for 1 h and mounted on glass slides using
Vectashield (Vector Laboratories, Southfield, MI). Serial
images were taken on a confocal TCS-SP2 laser-scanning
microscope with overlapped excitation and emission
wavelength removed (Leica Microsystems, Inc., Bannock-
burn, IL). Co-localization of SMN and p53 was visualized
in x-, y-, and z-planes using orthogonal views of stacked
images. Number of gems with or without co-localized
SMN/p53 per 100 cells was counted in control and each
type of SMA fibroblasts. Only gems sizes  0.5 m in
diameter were included because they can be easily
detected on a single orthogonal plane.
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